Cory Mavis
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 29
-
- Lymphoma Diagnosis and Treatment 37
- Oncology top 10%
- CAR-T cell therapy research 15
- Peptidase Inhibition and Analysis 9
- Hematology top 10%
- Multiple Myeloma Research and Treatments 8
-
- Ubiquitin and proteasome pathways 17
- Protein Degradation and Inhibitors 13
-
- Monoclonal and Polyclonal Antibodies Research 11
Cory Mavis
69 papers receiving 750 citations
Peers
Comparison fields: 5 of 72
- Genetics 159
- Pathology and Forensic Medicine 245
- Oncology 285
- Hematology 77
- Molecular Biology 441
Countries citing papers authored by Cory Mavis
This map shows the geographic impact of Cory Mavis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cory Mavis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cory Mavis more than expected).
Fields of papers citing papers by Cory Mavis
This network shows the impact of papers produced by Cory Mavis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cory Mavis. The network helps show where Cory Mavis may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Cory Mavis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 1 | |
| 7 | 2023 | 0 | |
| 8 | 2020 | 25 | |
| 9 | 2020 | 14 | |
| 10 | 2017 | 1 | |
| 11 | 2017 | 2 | |
| 12 | 2017 | 5 | |
| 13 | 2015 | 73 | |
| 14 | 2014 | 28 | |
| 15 | 2014 | 1 | |
| 16 | 2012 | 78 | |
| 17 | 2012 | 2 | |
| 18 | 2012 | 1 | |
| 19 | 2011 | 46 | |
| 20 | 2009 | 27 |
About Cory Mavis
Cory Mavis is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Radiology, Nuclear Medicine and Imaging, having authored 74 papers that have together received 754 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (37 papers), Chronic Lymphocytic Leukemia Research (29 papers), Ubiquitin and proteasome pathways (17 papers), CAR-T cell therapy research (15 papers), Protein Degradation and Inhibitors (13 papers), Monoclonal and Polyclonal Antibodies Research (11 papers), Peptidase Inhibition and Analysis (9 papers) and Multiple Myeloma Research and Treatments (8 papers). The work is most often cited by research in Genetics (159 citations), Pathology and Forensic Medicine (245 citations), Oncology (285 citations), Hematology (77 citations) and Molecular Biology (441 citations). Cory Mavis has collaborated with scholars based in United States, China and Czechia. Frequent co-authors include Francisco J. Hernandez‐Ilizaliturri, Myron S. Czuczman, Juan Gu, Matthew J. Barth, Qunling Zhang, John F. Gibbs, Kai Xue, George Deeb, Ye Guo and Michael Grau. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Oncotarget and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.